|
||||||||
Company Profile | ||||||||
Chairman | CEO | Spokesperson | Tel | Address | Date of Listing (Regular) | |||
---|---|---|---|---|---|---|---|---|
MAGNET LIN | LIN MING YI | CHAN,HUI-LIN | 06-5053288 | 1F., No.10, Lane 31, Sec. 1, Huandong Rd., Sinshih Dist.,Tainan City 744, Taiwan (R.O.C.) | 2012/01/10 | |||
Industry | Main Business | |||||||
Biotechnology and Medical Care | SunMax Biotechnology Co. Ltd., established in Feb. 2001, has been the first company of collagen R&D and manufacture in Taiwan. SunMax entered Tainan Science Park in July 2001, and then acquires Medical Device GMP certificate in January 2004. Earlier in Taiwan, biomedical collagen material and related products depended on importation, but most of them are extracted from bovines with potential BSE (Bovine Spongiform Encephalopathy). In 1995, under the supervision of key SunMax technical team in the US, SunMax R&D successfully developed an extraction and purification process to produce high purity medical grade collagen from SPF (Specific Pathogen Free) porcine skin in Taiwan. The process was scaled up in a GMP facility in Tainan Science Park. |
Market Information ( 2024/03/28 ) | |||||||||||
Shr. Vol. | Highest | Lowest | Closed | Change | Transaction | TurnOver(%) | long margin balance (1,000shr.) |
Short margin balance (1,000shr.) |
|||
---|---|---|---|---|---|---|---|---|---|---|---|
440.629 | 245.00 | 231.00 | 241.00 | 12.00 | 989 | .00 | 1,413 | 2 | |||
Trading method | Fun purchase price or securities pneeded on T day |
Announcement of Irregularity (2024/03/29) |
TPEx measures adopted (2024/03/29) |
With warrants | Can be shorted or margined? | Detail | |||||
Normal | N | N | N | N | Y | Today | History |
Financial Reports | |||||
---|---|---|---|---|---|
Cash Flows | Items | ||||
Amount (NT$ thousand) |
|||||
Cash flows from operating activities | |||||
Cash flows from investing activities | |||||
Cash flows from financing activities | |||||
Balance Sheets |
Current assets | ||||
Non-current assets | |||||
Total assets | |||||
Current liabilities | |||||
Non-current liabilities | |||||
Total liabilities | |||||
Share capital | |||||
Capital surplus | |||||
Retained earnings | |||||
Other equity interest | |||||
Treasury shares | |||||
Total equity attributable to owners of parent | |||||
Non-controlling interests | |||||
Total equity | |||||
Book Value per share(NT$) | |||||
Comprehensive Income | Operating revenue | ||||
Operating costs | |||||
Gross profit from operations | |||||
Operating expenses | |||||
Net other income (expenses) | |||||
Net operating income | |||||
Non-operating income and expenses | |||||
Profit before tax | |||||
Tax expense | |||||
Profit from continuing operations | |||||
Profit from discontinued operations | |||||
Profit | |||||
Other comprehensive income | |||||
Comprehensive income | |||||
Basic earnings per share |
Auditor's report on latest financial statements: auditor's report: |
More detail:MOPS。 |
Foreign issuers’ information is disclosed in consolidated statements. |